 REDWOOD CITY, Calif., June 10, 2021 GLOBE NEWSWIRE -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited Takeda for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four. 